HK1257177A1 - 肿瘤免疫治疗 - Google Patents

肿瘤免疫治疗 Download PDF

Info

Publication number
HK1257177A1
HK1257177A1 HK18116072.7A HK18116072A HK1257177A1 HK 1257177 A1 HK1257177 A1 HK 1257177A1 HK 18116072 A HK18116072 A HK 18116072A HK 1257177 A1 HK1257177 A1 HK 1257177A1
Authority
HK
Hong Kong
Prior art keywords
mirna
cells
promoter
nucleic acid
nucleotide sequence
Prior art date
Application number
HK18116072.7A
Other languages
English (en)
Chinese (zh)
Inventor
蒂莫西‧冠-塔‧卢
蒂莫西‧冠-塔‧盧
利奥尔‧尼西姆
吴名儒
利奧爾‧尼西姆
吳名儒
Original Assignee
麻省理工学院
麻省理工學院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 麻省理工学院, 麻省理工學院 filed Critical 麻省理工学院
Publication of HK1257177A1 publication Critical patent/HK1257177A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
HK18116072.7A 2015-06-19 2016-06-17 肿瘤免疫治疗 HK1257177A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562181906P 2015-06-19 2015-06-19
US62/181,906 2015-06-19
US201662325314P 2016-04-20 2016-04-20
US62/325,314 2016-04-20
PCT/US2016/038222 WO2016205737A2 (en) 2015-06-19 2016-06-17 Tumor immunotherapy

Publications (1)

Publication Number Publication Date
HK1257177A1 true HK1257177A1 (zh) 2019-10-18

Family

ID=57546436

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116072.7A HK1257177A1 (zh) 2015-06-19 2016-06-17 肿瘤免疫治疗

Country Status (7)

Country Link
US (1) US20190002912A1 (https=)
EP (1) EP3310915A4 (https=)
JP (1) JP2018520669A (https=)
CN (1) CN108350445A (https=)
AU (1) AU2016279050A1 (https=)
HK (1) HK1257177A1 (https=)
WO (1) WO2016205737A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102763121B1 (ko) 2015-02-06 2025-02-04 내셔널 유니버시티 오브 싱가포르 치료적 면역 세포의 효능의 향상 방법
WO2018022747A1 (en) 2016-07-26 2018-02-01 Senti Biosciences, Inc. Genetic erasers
WO2018169901A1 (en) * 2017-03-13 2018-09-20 Massachusetts Institute Of Technology Synthetic promoters
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
CN112654711B (zh) * 2018-08-29 2024-03-26 上海科技大学 Cas蛋白抑制剂的组合物及应用
US12398428B2 (en) * 2019-02-06 2025-08-26 Cornell University DARC expression as prognosticator of immunotherapy outcomes
JP2023504884A (ja) * 2019-12-05 2023-02-07 ヴィセリックス・インコーポレーティッド ユニバーサル細胞療法のための免疫逃避機構のモジュレーター
CN116859048A (zh) * 2022-12-09 2023-10-10 上海交通大学医学院附属第九人民医院 肿瘤标志物跨膜蛋白slc31a1及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
WO2008134593A1 (en) * 2007-04-25 2008-11-06 President And Fellows Of Harvard College Molecular circuits
EP3444346B1 (en) * 2010-04-23 2022-07-27 University of Massachusetts Aav-based treatment of cholesterol-related disorders

Also Published As

Publication number Publication date
US20190002912A1 (en) 2019-01-03
WO2016205737A3 (en) 2017-02-02
AU2016279050A1 (en) 2018-01-04
EP3310915A2 (en) 2018-04-25
WO2016205737A2 (en) 2016-12-22
AU2016279050A2 (en) 2018-01-04
JP2018520669A (ja) 2018-08-02
CN108350445A (zh) 2018-07-31
EP3310915A4 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
Zhang et al. Challenges and new technologies in adoptive cell therapy
Rui et al. Cancer immunotherapies: advances and bottlenecks
HK1257177A1 (zh) 肿瘤免疫治疗
Zheng et al. Oncolytic viruses for cancer therapy: barriers and recent advances
Miao et al. Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors
JP7710644B2 (ja) 複数の抗原を標的とするｃｏｍｐｏｕｎｄキメラ抗原受容体（ｃＣＡＲ）の組成物およびその使用方法
CN114350613B (zh) Suv39h1缺陷的免疫细胞
KR102338993B1 (ko) 인위적으로 조작된 조작면역세포
Brücher et al. iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy
WO2015075469A1 (en) Cell
Nasiri et al. Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies
Li et al. Precision sniper for solid tumors: CAR-NK cell therapy
Kontermann et al. Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics
Dash et al. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review
Yin et al. Translating synthetic gene circuits into the clinic: Challenges, opportunities, and future directions
Jassaud et al. Innate immune cells in chimeric antigen receptor therapy
Liu et al. Synthetic biology approaches to enhance cancer immune responses
Mirzaee Godarzee et al. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy
Liu et al. Harnessing NKG2D CAR-T cells with radiotherapy: a novel approach for esophageal squamous cell carcinoma treatment
Vachani et al. Gene therapy for lung neoplasms
CN106467576B (zh) 一种抗体融合蛋白及其制备方法与应用
Esmaeilzadeh et al. Chimeric antigen receptor (CAR) T Cell immunotherapy for solid tumors
Khodabandehloo et al. Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors
Chen et al. Synthetic immunity to break down the bottleneck of cancer immunotherapy
US20220152134A1 (en) Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada